CHF 40,000 for a minimally invasive diagnostic for sepsis, expert ultrasound access, and direct-to-consumer health risk assessment
15.07.2024
EVIIVE, Scanvio, and TrueYouOmics were selected at Venture Kick's second financial and entrepreneurial support stage. Their projects provide a diagnostic and disease monitoring approach for sepsis patients that is minimally invasive, sensitive, and specific to serve as a navigation tool for precise treatment; democratize expert ultrasound; and offer a comprehensive multi-omic health risk assessment by integrating DNA, RNA, and Protein data from a blood sample, going beyond just predisposition.
 |
 |
 EVIIVE: CSO Dr. Richard Chahwan
|
|
 Scanvio Medical: CTO Fabian Laumer and CEO Stefan Tuchschmid
|
|
 TrueYouOmics: from left to right, Dominic Mehr (CCO), Kevin Yar (CEO), Andres Lanzos (CSO)
|
|
EVIIVE: minimally invasive diagnostic for sepsis
The current standard of care approach for sepsis is highly invasive, delayed, and insensitive.
CEO Dr. Kevin Ho Wai Yim from UZH co-founded EVIIVE with CSO Dr. Richard Chahwan to provide a diagnostic and disease monitoring approach for sepsis patients that is minimally invasive, sensitive, and specific to serve as a navigation tool for precise treatment. The solution uses liquid biopsies derived from extracellular vesicle analyses for sepsis detection and monitoring. The final product will be assay kits for customers to process liquid biopsies and analyze with existing flow cytometers. They are also planning to provide novel EVs biomarker discovery services for diseases with high unmet needs in detection and monitoring. In the EU/US, around 20% of newborns (around 1,600,000 per year) show sepsis symptoms, and over 75,000 children are diagnosed with severe sepsis every year in the US with a similar number in the EU (around 150,000 per year). At the target charge of USD 100 per test, with each patient taking 3 tests for 3 days after symptoms onset, the revenue is estimated at approximately USD 525 million per year.
The Venture Kick funds will cover the salary of a research assistant to perform validation experiments and associated reagent costs and equipment charges.
Scanvio Medical: Democratize expert ultrasound
Endometriosis affects 10% of all women, and it takes an average of 8–12 years to get a diagnosis. The medical condition can cause heavy pain, excessive bleeding, and infertility, and the diagnosis typically requires an invasive laparoscopic surgery.
Scanvio uses AI to empower every gynecologist to diagnose endometriosis during a standard ultrasound examination. The company’s machine learning solution detects and highlights telltale signs of endometriosis in a noisy ultrasound video, and targets the USD 1.6 B AI in the ultrasound market, a subset of the USD 8.5B medical ultrasound equipment market.
CTO Dr. Fabian Laumer developed intelligent algorithms for ultrasound interpretation during his ETH Ph.D. research and is now taking advantage of the decades of OB/GYN experience amassed by CMO Prof. Michael Bajka, M.D. Scanvio’s founding team also includes CEO and serial entrepreneur Dr. Stefan Tuchschmid, Julian Metzler, M.D., Gabriel Fringeli, and Prof.Dr. Joachim Buhmann.
Thanks to the Venture Kick prize money, Scanvio will be able to build a first product demonstrator and showcase the concept at the annual meeting of the Swiss Society for Gynecology and Obstetrics at the end of June. scanvio.com
TrueYouOmics: The most comprehensive Direct-to-Consumer health risk assessment
Today’s healthcare systems focus on treating diseases rather than preventing them leading to late detection, unnecessary suffering, and early deaths. Existing solutions have limitations in terms of scope and often ignore highly relevant lifestyle & environmental factors.
TrueYouOmics offers a comprehensive multi-omic health risk assessment by integrating DNA, RNA, and Protein data from a blood sample, going beyond just predisposition. Its approach combines biomedical knowledge graphs, network models, and medical LLMs for disease risk predictions and preventive planning. The startup empowers individuals with health control and saves MDs time in screening and diagnostics. The team combines 25 years of experience in Biotech, AI, Pharma, and Startups to tackle this multi-billion market.
The Venture Kick will be used in reaching the next milestones, including the pilot, go-to-market strategy, and building the foundation for the MVP launch in early 2025.
The current standard of care approach for sepsis is highly invasive, delayed, and insensitive.
CEO Dr. Kevin Ho Wai Yim from UZH co-founded EVIIVE with CSO Dr. Richard Chahwan to provide a diagnostic and disease monitoring approach for sepsis patients that is minimally invasive, sensitive, and specific to serve as a navigation tool for precise treatment. The solution uses liquid biopsies derived from extracellular vesicle analyses for sepsis detection and monitoring. The final product will be assay kits for customers to process liquid biopsies and analyze with existing flow cytometers. They are also planning to provide novel EVs biomarker discovery services for diseases with high unmet needs in detection and monitoring. In the EU/US, around 20% of newborns (around 1,600,000 per year) show sepsis symptoms, and over 75,000 children are diagnosed with severe sepsis every year in the US with a similar number in the EU (around 150,000 per year). At the target charge of USD 100 per test, with each patient taking 3 tests for 3 days after symptoms onset, the revenue is estimated at approximately USD 525 million per year.
The Venture Kick funds will cover the salary of a research assistant to perform validation experiments and associated reagent costs and equipment charges.
Scanvio Medical: Democratize expert ultrasound
Endometriosis affects 10% of all women, and it takes an average of 8–12 years to get a diagnosis. The medical condition can cause heavy pain, excessive bleeding, and infertility, and the diagnosis typically requires an invasive laparoscopic surgery.
Scanvio uses AI to empower every gynecologist to diagnose endometriosis during a standard ultrasound examination. The company’s machine learning solution detects and highlights telltale signs of endometriosis in a noisy ultrasound video, and targets the USD 1.6 B AI in the ultrasound market, a subset of the USD 8.5B medical ultrasound equipment market.
CTO Dr. Fabian Laumer developed intelligent algorithms for ultrasound interpretation during his ETH Ph.D. research and is now taking advantage of the decades of OB/GYN experience amassed by CMO Prof. Michael Bajka, M.D. Scanvio’s founding team also includes CEO and serial entrepreneur Dr. Stefan Tuchschmid, Julian Metzler, M.D., Gabriel Fringeli, and Prof.Dr. Joachim Buhmann.
Thanks to the Venture Kick prize money, Scanvio will be able to build a first product demonstrator and showcase the concept at the annual meeting of the Swiss Society for Gynecology and Obstetrics at the end of June. scanvio.com
TrueYouOmics: The most comprehensive Direct-to-Consumer health risk assessment
Today’s healthcare systems focus on treating diseases rather than preventing them leading to late detection, unnecessary suffering, and early deaths. Existing solutions have limitations in terms of scope and often ignore highly relevant lifestyle & environmental factors.
TrueYouOmics offers a comprehensive multi-omic health risk assessment by integrating DNA, RNA, and Protein data from a blood sample, going beyond just predisposition. Its approach combines biomedical knowledge graphs, network models, and medical LLMs for disease risk predictions and preventive planning. The startup empowers individuals with health control and saves MDs time in screening and diagnostics. The team combines 25 years of experience in Biotech, AI, Pharma, and Startups to tackle this multi-billion market.
The Venture Kick will be used in reaching the next milestones, including the pilot, go-to-market strategy, and building the foundation for the MVP launch in early 2025.